Trial Profile
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of ZN-e4 (KP-673) in Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor (EGFR) Mutations
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Jan 2024
Price :
$35
*
At a glance
- Drugs ZN-e4 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Zeno Pharmaceuticals
- 02 Dec 2022 Status changed from active, no longer recruiting to completed.
- 03 May 2022 Status changed from recruiting to active, no longer recruiting.
- 28 Jun 2021 According to a Zentalis Pharmaceuticals media release, 26 patients (both osimertinib-naive and experienced) enrolled to date. ZN-e4 has been well-tolerated at all doses as of the March 25, 2021 data cut-off, and clinical activity was identified at doses greater than 80 mg QD. Interim results from the Phase 1/2 trial are expected in 4Q 2021.